Sobi Unveils New Data on Rare Disease Therapies at EHA 2026
Event summary
- Sobi will present new clinical and real-world data on Aspaveli, Doptelet, Gamifant, and Vonjo at EHA 2026 in Stockholm, June 11–14, 2026.
- Presentations cover rare diseases including PNH, ITP, HLH, and myelofibrosis.
- Data includes real-world evidence and post hoc analyses for key therapies.
- Sobi collaborates with Apellis (now part of Biogen) on pegcetacoplan development and commercialization.
The big picture
Sobi's data presentations at EHA 2026 underscore its focus on rare hematologic diseases, where therapeutic options remain limited. The company's collaborations, particularly with Apellis (now part of Biogen), highlight its strategy of co-developing and commercializing specialized therapies. With revenue of SEK 28 billion in 2025, Sobi is positioning itself as a key player in the rare disease space, where clinical differentiation and real-world evidence are critical for market access and reimbursement.
What we're watching
- Clinical Validation
- Whether the new data strengthens the clinical profiles of Sobi's rare disease therapies, particularly in high-unmet-need areas.
- Commercial Strategy
- How Sobi leverages these insights to differentiate its portfolio in competitive rare disease markets.
- Regulatory Pathways
- The pace at which real-world evidence could support expanded indications or label updates for key products.
Related topics